Chronic treatment with Δ9-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction

Neuropharmacology

Volumn 41, Issue 1, 2001, Pages 118-129

  Lamarque, S ^a   Taghzouti, K ^b   Simon, H ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b FACULTÉ DES SCIENCES   (Morocco)

Author keywords

Amphetamine; Chronic treatment; Cross sensitization; Heroin; Locomotor activity; 9 THC

Indexed keywords

AMPHETAMINE; CANNABIS DERIVATIVE; DIAMORPHINE; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; BEHAVIOR; COLD TOLERANCE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG RESPONSE; DRUG SENSITIZATION; DRUG USE; HYPOTHESIS; LOCOMOTION; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0034976121     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(01)00039-9     Document Type: Article

References (94)

1. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR141716A
2. 9-tetrahydrocannabinol in mice on intestinal motility, temperature and locomotor activity
3. Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP55,940 on behavioral sensitization to cocaine
4. Reversal of dopamine D(2) receptor response by an anandamide transporter inhibitor
5. The effects of cannabinoids on body temperature and brain catecholamine synthesis
6. Regional brain homovanillic acid following delta9-tetrahydrocannabinol and cocaine
7. Potentiation of amphetamine-induced arousal by starvation
8. Evaluation of a suspension system for intravenous self-administration studies of water insoluble compounds in the rhesus monkey
9. THC does not affect striatal dopamine release: Microdialysis in freely moving rats
10. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats
11. 9-Tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely moving rats as measured by intracerebral microdialysis
12. 9-Tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex
13. 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus
14. 9-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat
15. Reluctance of rats to drink hashish suspensions: Free choice and forced consumption, and the effects of hypothalamic stimulation
16. 9-tetrahydrocannabinol on body temperature in mice
17. Repeated corticosterone administration sensitizes the locomotor response to amphetamine
18. Sensitization to the psychomotor effects of amphetamine and morphine induces by food restriction depends on corticosterone secretion
19. Cannabinoid pharmacology
20. Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats: Electrophysiological and biochemical evidence
21. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats
22. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids
23. Mesolimbic dopaminergic decline after cannabinoid withdrawal
24. The role of dopamine in drug abuse viewed from the perspective of its role in motivation
25. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerants rats
26. Cannabinoids and the hippocampal glucocorticoid receptor: Recent findings and possible signifiance
27. 9-Tetrahydrocannabinol: Aversive effects in rat at high doses
28. The effect of Δ9-tetrahydrocannabinol on body temperature and brain amine concentrations in the rat at different ambient temperatures
29. Influence of the cannabinoid agonist HU210 on cocaine- and CQP201-403-induced behavioural effects in rat
30. 9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors
31. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra
32. Isolation, structure and partial synthesis of an active constituent of hashish
33. 9-tetrahydrocannabinol
34. The effect of intravenous administration of delta9-tetrahydrocannabinol on the activity of A10 dopamine neurons recorded in vivo in anesthetized rats
35. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
36. 9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats
37. 9-tetrahydrocannabinol in rhesus monkeys
38. 9-tetrahydrocannabinol: Neurochemical and behavioural effects in the mouse
39. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta9-tetrahydrocannabinol
40. 9-tetrahydrocannabinol, cannabidiol and schock on plasma corticosterone in rats
41. 8-THC) on water intake in water deprived rats: Implications for behavioral studies on marihuana compounds
42. Stages in adolescent involvement in drug use
43. Cellular and molecular mechanisms of drug dependance
44. Effect of early exposure to delta-9-tetrahydrocannabinol on the levels of opioid peptides, gonadotropin-releasing hormone and substance P in the adult male rat brain
45. 1 receptor knockout mice
46. Failure to obtain cannabis directed behavior and abstinence syndrome in rats chronically treated with cannabis sativa extracts
47. 9-tetrahydrocannabinol: Comparison with cocaine, morphine and food reward
48. Acute tolerance to the hypothermic effect of marihuana in the rat
49. 9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance
50. 9-tetrahydrocannabinol
51. 9-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed interval schedule in rhesus monkeys
52. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain
53. Pharmacological and biochemical interactions between opioids and cannabinoids
54. 9-tetrahydrocannabinol in rats
55. Self-administration of the cannabinoid receptor agonist win 55,212-2 in drug-naive mice
56. Aversive effects of the synthetic cannabinoid CP55,940 in rats
57. 1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependant rats
58. THC-induced place and taste aversion in Lewis and Sprague-Dawley rats
59. Tolerance to and dependence on psychotropic cannabinoids
60. Factors that predict individual vulnerability to amphetamine self-administration
61. Corticosterone levels determine individual vulnerability to amphetamine self-administration
62. Dopamine activity is reduced in the prefrontal cortex and increased in the nucleus accumbens of rats predisposed to develop amphetamine self-administration
63. Corticosterone in the range levels possesses reinforcing properties: Implications for sensation-seeking behaviors
64. Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats
65. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
66. Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats
67. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal
68. Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol
69. Cannabinoid-precipitated withdrawal: A time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression
70. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat
71. Schedule-induced self-injection of drugs
72. 8-THC) on body weight, food, and water in rats
73. 9-tetrahydrocannabinol
74. 9-tetrahydrocannabinol on rectal temperature in rats
75. 9-tetrahydrocannabinol on food intake by rats
76. Cannabinoids. I Behavioral effects
77. Interindividual differences in active and passive behaviors in the forced swimming test: Implications for animals models of psychopathology
78. Self-administration of delta9-tetrahydrocannabinol by rats
79. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism
80. 9-tetrahydrocannabinol
81. 9-tetrahydrocannabinol on body temperature and brain amines of the rat
82. 9-tetrahydrocannabinol in the rat
83. Effects of delta9-tetrahydrocannabinol on the release of dopamine in the corpus striatum of the rat
84. 9-tetrahydrocannabinol in mice
85. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist
86. The effects of morphine and delta9-tetrahydrocannabinol on motor activity in rats
87. 9-tetrahydrocannabinol in mice
88. Intravenous self-administration of drugs in rats
89. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine
90. Effects of 9-tetrahydrocannabinol and ethyl alcohol on adjunctive behavior and the lateral hypothalamus
91. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice
92. A psychomotor stimulant theory of addiction
93. Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: An electrophysiological assessment
94. Pattern of drug use from adolescence to young adulthood: III. Predictors of progression